Financial Performance - The company's operating revenue for the first nine months of 2023 was ¥166,457,498.73, a decrease of 18.16% compared to ¥203,399,308.70 in the same period last year[11] - The net profit attributable to shareholders for the first nine months of 2023 was ¥40,209,651.19, down 9.49% from ¥44,425,698.99 in the previous year[11] - The basic earnings per share for the third quarter of 2023 was ¥0.10, a decrease of 69.70% compared to ¥0.33 in the same period last year[11] - Operating revenue for the first nine months of 2023 was CNY 125,687,295.86, a decrease of 35.4% compared to CNY 194,628,012.10 in the same period of 2022[39] - Net profit for the first nine months of 2023 was CNY 41,683,528.09, slightly up from CNY 41,155,742.62 in 2022, representing a 1.3% increase[40] - The company reported a net profit margin decline due to reduced operating revenue, impacting overall profitability metrics[36] Cash Flow and Liquidity - The net cash flow from operating activities decreased by 26.83% to ¥35,512,165.26 from ¥48,535,743.01 in the same period last year[11] - The company's cash and cash equivalents decreased from 79,993,985.09 to 66,472,447.82, a decline of approximately 16.3%[28] - The ending cash and cash equivalents balance as of September 2023 was CNY 49,427,711.44, up from CNY 15,690,684.55 at the end of the same period in 2022[45] - The company reported a net decrease in cash and cash equivalents of CNY -5,126,819.76 for the first nine months of 2023, compared to a decrease of CNY -31,162,144.27 in the same period of 2022[45] - The total cash outflow for operating activities was CNY 117,169,546.11, down from CNY 171,411,173.92 in the same period last year[45] Assets and Liabilities - The total assets as of September 30, 2023, were ¥520,197,953.72, an increase of 36.64% from ¥380,716,880.35 at the end of the previous year[12] - The total current assets increased significantly from 211,003,184.81 to 349,814,609.38, reflecting a growth of about 65.8%[28] - Total liabilities rose to ¥59.55 billion in September 2023, compared to ¥55.86 billion in December 2022, an increase of 3.0%[30] - Shareholders' equity reached ¥460.65 billion in September 2023, up from ¥324.86 billion in December 2022, reflecting a growth of 42.0%[30] Inventory and Receivables - The company's inventory increased by 33.96% to ¥90,243,326.52, attributed to increased production and stockpiling[13] - Inventory levels rose from 67,368,365.91 to 90,243,326.52, an increase of approximately 33.9%[28] - The accounts receivable decreased from 32,513,780.98 to 24,100,804.06, a reduction of about 26.1%[28] - Accounts receivable increased to ¥26.93 billion in September 2023, compared to ¥25.68 billion in December 2022, an increase of 4.9%[32] Shareholder Information - The total number of shares outstanding is 40,157,500, with 47.86% being unrestricted shares and 52.14% being restricted shares[18] - The largest shareholder, Dong Laishan, holds 15,741,786 shares, representing 39.2% of total shares[20] - The total number of shareholders holding common stock is 2,201[18] - There are no pledged or frozen shares among the top shareholders[21] Government Support and Other Income - The company received government subsidies totaling ¥14,976,478.87, contributing to its non-recurring gains[16] - Other income for the first nine months of 2023 was CNY 751,349.39, significantly lower than CNY 4,201,127.10 in 2022, a decrease of 82.1%[40] Investment Activities - Cash inflow from investment activities totaled CNY 91,350,194.31, compared to CNY 98,809,425.18 in the previous year, reflecting a decline of approximately 7.4%[45] - The net cash outflow from investment activities was CNY -138,661,321.25, significantly higher than CNY -46,621,155.80 in 2022, indicating increased investment expenditures[45] - The company received CNY 110,936,330.73 from investment absorption during the reporting period[45] Research and Development - Research and development expenses for the first nine months of 2023 were CNY 8,146,100.52, an increase of 15.4% compared to CNY 7,055,676.81 in 2022[40]
峆一药业(430478) - 2023 Q3 - 季度财报